ABSTRACT
INTRODUCTION
Small molecule multi-targeted receptor tyrosine kinase inhibitors (TKIs) represent a clinically relevant strategy for patients with advanced tumors such as renal cell carcinoma (RCC) and gastrointestinal stromal tumors (GISTs) (1, 2) . It has been reported that sunitinib's tumoricidal activity is mediated mainly through inhibition of the platelet-derived growth factor receptor (PDGFR), the vascular endothelial growth factor receptor (VEGFR) 1 and 3, KIT, and fms-related tyrosine kinase 3 (FLT3) (3) . In Phase III clinical trials with sunitinib, median survival for patients with metastatic RCC increased from 10 to 24 months (4). As such, sunitinib received approval by the Food and Drug Administration for the treatment of metastatic RCC in 2006. Due to its remarkable success with metastatic RCC, the drug is also under intense investigation as a treatment for several other cancers, including breast, colorectal, and non-small cell lung (3).
More recently, initial clinical experience with sunitinib in castration-resistant prostate cancer (CRPC) patients has been reported. In Phase II trials, a heterogeneous response to sunitinib was noted in both docetaxel-resistant and chemotherapy naïve patients with a significant proportion of tumors demonstrating at least a partial radiographic response. In the most recent study of subjects with docetaxel-resistant CRPC, 11 .1% of patients demonstrated 30% tumor reduction by Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Another 44.4% of patients had quantifiable but less significant tumor response (5) .
Drug resistance to anti-cancer therapies remains a clinical challenge. Tumors may acquire stability to the drug during treatment or show intrinsic resistance from the outset of therapy. One possible mechanism implicated in TKI resistance may be the constitutive activation of various intracellular pro-tumorigenic pathways downstream of receptor signaling. Activation of the PI3K/Akt/mTOR pathway, chiefly due to redundant autocrine signaling rather than mutations, is clearly involved in tumor initiation and progression (6) . The PI3K/Akt/mTOR axis is a central crossroad of many intracellular signaling pathways, exhibiting direct and indirect control over a multitude of cellular events including cell cycle progression, cellular proliferation/growth, autophagy, and angiogenesis (6).
The tumor suppressor phosphatase and tensin homolog (PTEN) acts as a gatekeeper of the PI3K/Akt/mTOR cell-survival signaling pathway. Under normal cellular conditions, PTEN is a negative regulator of tumorigenic activity; however, when lost or inactivated, the PI3K/Akt/mTOR pathway is enhanced. As such, loss of PTEN can be an indicator of aggressive behavior in tumors of various cell types (6) . In our present study, we found that that the status of PTEN expression inversely correlates with sunitinib resistance in renal and prostate cancer cells. Induced expression of PTEN in PTEN-negative tumor cells markedly increased tumor sensitivity to sunitinib both in vitro and in vivo. Furthermore, we were able to circumvent sunitinib resistance in PTEN-negative tumor cells by manipulation of PI3K/Akt/mTOR signaling with pharmacologic agents such as GDC-0980, GSK690693 and temsirolimus. These results indicate that lack of PTEN expression may contribute to intrinsic sunitinib resistance, and the activity of the PI3K/Akt/mTOR pathway may be a marker of TKI response/resistance in genitourinary tumors. Furthermore, coadministration of sunitinib with PI3K/Akt/mTOR inhibitors may represent a rational treatment strategy for patients with resistant urologic tumors. 
Antibodies and Reagents
Antibodies to PTEN, Akt, phospho-Akt(S473), phospho-Akt(T308), phosphoTuberin/TSC2(T1462), Tuberin/TSC2, phospho-4EBP1(T37/46) and GAPDH were obtained from Cell Signaling Technology (Beverly, MA). Sunitinib and temsirolimus were obtained from LC Laboratories (Woburn, MA). GDC-0980 was obtained from ChemieTek (Indianapolis, IN).
GSK690693 was obtained from Selleck (Houston, TX).

Stable Transfection with PTEN
To generate the PTEN expression vector PTEN ORF was amplified with specific forward 5`-atcttgaagcttgccaccatgacagccatcatcaaag-3` and reverse 5`-atcttggaattctcagacttttgtaatttgtgtatgctgatc- Selection was performed using puromycin (1 μg/ml).
Western Blot Analysis
Whole cell lysates preparation and Western Blot Analysis were performed as described previously (7) .
Measurement of apoptosis
DNA fragmentation was detected using the APO-BRDU kit (The Phoenix Flow Systems, Inc., San Diego, CA) according to manufacturer's instructions.
Measurement of IL-6 and IL8
IL-6 and IL-8 levels in cell culture supernatants were measured using ELISA kits (R&D Systems, Minneapolis, MN).
Assessment of in vivo tumor growth.
For in vivo studies, 1 x 10 6 PC-3-PTEN or PC-3-puromycin cells were inoculated s.c. in the flank region of 6 week-old male C.B17/Icr-scid mice using a 27-gauge needle. 
Statistical analysis
Statistical analysis was performed using a two-sided Student's t-test. A p-value of <0.05
was considered statistically significant. 
RESULTS
Lack of PTEN expression coincides with sunitinib resistance in renal and prostate cancer cells in vitro.
To investigate the potential mechanisms underlying TKI resistance in vitro, we first analyzed the effect of sunitinib on the viability of several renal and prostate cancer cell lines. The findings presented in Figure 1A demonstrate that sunitinib was capable of inducing a significant level of apoptosis in seven out of the ten renal and prostate cancer cell lines tested with the notable exception of 786-0 (renal) and PC-3 and LNCaP (prostate) cancer cell lines. These three cell lines were nearly completely resistant to sunitinib-mediated apoptosis. Since constitutive activation of the PI3K/Akt/mTOR pathway due to deletion or mutation of PTEN expression has been detected in a large percentage of the most common human cancers (6, 8) , we analyzed the status of PTEN expression in these ten cell lines. As shown in Figure 1B , PTEN expression was undetectable in the sunitinib-resistant 786-0, PC-3 and LNCaP cells. All other cell lines that were sensitive to sunitinib-mediated apoptosis manifested PTEN positivity.
To validate our observation that PTEN expression modulates the sensitivity of malignant cells to sunitinib, we generated 786-0 renal and PC-3 prostate cancer cell lines capable of expressing PTEN (Fig. 2A) . Consistent with the role of PTEN as a negative regulator of PI3K/Akt/mTOR signaling pathway, the level of Akt phosphorylation was markedly reduced in PTEN-expressing cells compared with 786-O and PC-3 cells transfected with the control vector ( Fig. 2A) . With successful restoration of PTEN expression in previously PTEN-deficient 786-0 and PC-3 cells, a pronounced sensitivity to sunitinib-mediated apoptosis was attained (Fig. 2B) . To extend our in vitro findings to the in vivo setting, xenograft tumors were established in SCID mice using PC-3 cells that exhibited stable expression of PTEN. Control tumors were established using PTEN-negative PC-3 cells transfected with the control vector as described above.
In addition, a xenograft model was created using 786-O and 786-O-PTEN tumors, however it was severely limited by the slow and unpredictable growth of both populations of cells to make its use practical. Animals were treated with vehicle alone or sunitinib (40 mg/kg) through oral gavage.
Vehicle-treated animals uniformly showed a progressive increase in primary tumor growth. In contrast, tumor growth was consistently and markedly reduced in animals carrying PC-3-PTEN xenografts treated with sunitinib (p<0.001) (Fig. 3A) . Treatment with sunitinib also caused an observable decrease in the growth of tumors established from control PC-3 cells (Fig. 3A) , (Fig. 3B) . It is important to underscore that whereas plasma levels of sunitinib were within a low micromolar range, intratumoral sunitinib concentrations were significantly higher (mean ± SEM: 5.4 ± 0.8ȝM versus 66.7 ± 15.8ȝM respectively) ( Table 1) . Our data confirms recent findings by Gotink et. al. demonstrating that intratumor sunitinib concentrations in the murine Renca RCC model and tumor tissue specimens obtained from cancer patients were 10-fold higher than the corresponding plasma concentrations (11) . Indeed, our in vivo findings confirm the crucial role of PTEN status as a marker of sensitivity to sunitinib and provide further validation that sunitinib has a direct effect on tumor cells, which extends beyond the established angiogenic inhibitory actions.
Pharmacological manipulation of PI3K/Akt/mTOR signaling enhances anti-tumor efficacy of sunitinib in vitro and in vivo.
In order to explore a clinically relevant strategy to manipulate the PI3K/Akt/mTOR pathway in cells exhibiting sunitinib resistance, we pre-incubated parental PTEN-negative 786-O and PC-3 cells with pharmacologic inhibitors of PI3K/Akt/mTOR signaling -GDC-0980, a selective, dual PI3K/mTOR inhibitor, GSK690693, a pan-Akt inhibitor, and temsirolimus, an mTOR inhibitor (Fig. 4A) . Temsirolimus is currently approved by the FDA for the treatment of advanced RCC (12) . Phase I clinical trials for GDC-0980 and GSK690693 are currently recruiting participants (13, 14) . The cytotoxic effect of sunitinib in combination with either GDC-0980, GSK690693 or temsirolimus was evaluated using the DNA fragmentation assay (Fig. 4B) . As (Fig. 4D ).
In light of our encouraging in vitro data, we next examined the anti-tumor effects of sunitinib in combination with temsirolimus using a mouse xenograft model bearing PTENnegative PC-3 tumors. Three weeks after the initiation of therapy, single agent treatment with temsirolimus or sunitinib showed a notable decrease in the growth of xenograft tumors (Fig. 4E) .
However, combination treatment with sunitinib and temsirolimus resulted in vastly more impressive inhibition of tumor growth among the experimental groups. These results confirm the importance of PTEN as an important surrogate for tumor cell resistance to TKIs but also provide pre- (Fig. 5 ). As such, additional pharmacologic modulation is required to suppress aberrant Akt activity. To elaborate further, we conclude that inhibition of Akt signaling alone is incapable of inducing apoptosis due to the existence of Akt-independent survival pathways. Thus, only concomitant administration of sunitinib and PI3K/Akt/mTOR inhibitors is capable of triggering apoptosis in PTEN-negative cancer cells.
DISCUSSION
The ability of multi-targeted TKIs to inhibit angiogenesis, and thereby affect tumor progression, has been well-established (3, 18) . Recent studies make evident that sunitib's sole influence stems from its anti-angiogenic effect, further emphasizing its lack of ability to exert a direct anti-tumor effect. These observations are based on the notion that pharmacologically 
